Related Experiment Video
Updated: Apr 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
BRD2 is a transcriptional coactivator of Smad3 in mediating TGF-β tumor suppressive responses
Shuai Tian1,2,3, Shuchen Gu4,5,6, Shuangwu Sun1,2,3
1MOE Key Laboratory of Biosystems Homeostasis & Protection and Zhejiang Key Laboratory of Molecular Cancer Biology, Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.
Abstract:
Transforming growth factor-β (TGF-β) is a multifunctional cytokine that regulates cell proliferation, differentiation, migration, and apoptosis. It is generally accepted that TGF-β induces cellular responses through Smad-dependent gene transcription. However, the underlying mechanisms that modulate the transcriptional activities of Smads are not yet fully understood. Here, we identify BRD2, a member of the bromodomain and extraterminal (BET) family, as a key transcriptional coactivator for Smad3. BRD2 physically interacts with Smad3 through a newly identified Smad3-binding region (SBR). This BRD2-Smad interaction enhances Smad's association with chromatin and amplifies its transcriptional activity, playing a vital role in TGF-β transcriptional and tumor-suppressive responses. Our findings establish BRD2 as an important modulator of TGF-β signaling and suggest that it may serve as a potential target for TGF-β-related diseases.
Insights
Bromodomain and extraterminal (BET) protein BRD2 acts as a coactivator for Smad3, enhancing transforming growth factor-β (TGF-β) signaling. This discovery reveals BRD2
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Transforming growth factor-β (TGF-β) is a cytokine regulating crucial cellular processes like proliferation and apoptosis.
- TGF-β signaling primarily occurs via Smad-dependent gene transcription, but regulatory mechanisms remain unclear.
Purpose of the Study:
- To identify novel coactivators that modulate Smad transcriptional activity.
- To elucidate the role of BRD2 in TGF-β signaling pathways.
Main Methods:
- Co-immunoprecipitation assays to detect protein interactions.
- Chromatin immunoprecipitation to assess Smad binding.
- Reporter gene assays to measure transcriptional activity.
Main Results:
- BRD2 was identified as a key transcriptional coactivator for Smad3.
- BRD2 physically interacts with Smad3 via a novel Smad3-binding region (SBR).
- BRD2 enhances Smad3's chromatin association and transcriptional activity, crucial for TGF-β responses.
Conclusions:
- BRD2 is a vital modulator of TGF-β signaling, impacting tumor-suppressive functions.
- The BRD2-Smad3 interaction presents a potential therapeutic target for TGF-β-related diseases.
Related Concept Videos
TGF - β Signaling Pathway
Abnormal Proliferation
Co-activators and Co-repressors
Master Transcription Regulators
Master Transcription Regulators
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

